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PEGylated nanoemulsions (NEs) can increase target site concentration of the incorporated 
active by increasing circulation time of the oil droplets [1]. Using experimental design 
approach best preparation conditions were chosen for further research. Curcumin was used 
as a model drug and incorporated into formulations selected by experimental design. The aim 
of this study was to follow the stability of PEGylated and the non-PEGylated NEs and to assess 
the impact of PEGylated phospholipids’ (PEG-PLs) addition on nanoemulsions’ long term 
stability. Additionally, the impact of PEG-PLs on drug release was assessed through in vitro 
drug release studies in order to choose the best candidates for in vivo pharmacokinetic study. 
NEs were prepared by high pressure homogenization [2]. Nanoemulsions’ stability was 
followed for 12 months by measuring mean droplet size (Z-ave), polydispersity index (PDI) and 
zeta potential (ZP). Drug release was studied by reverse dialysis bag method. 
Initial Z-ave of all NEs (103–106 nm), PDI (< 0.2) and ZP around –40 mV, suggested they are 
adequate for parenteral application. After 12 months these parameters did not significantly 
change. During in vitro release study the biggest release of curcumin was from the formulation 
containing 0.3% of PEG5000DPPE (43.38%) vs the lowest with 0.1 % of PEG2000DSPE (25.88%). 
This study showed the usefulness of D-optimal factorial design in NEs development. 
Formulations containing 0.1 % of PEG2000DSPE/PEG5000DPPE were chosen for further step - 
a pharmacokinetic study. 
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